168 related articles for article (PubMed ID: 11095134)
21. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
DeMario MD; Ratain MJ; Vogelzang NJ; Mani S; Vokes EE; Fleming GF; Melton K; Johnson S; Benner S; Lebwohl D
Cancer Chemother Pharmacol; 1999; 43(5):385-8. PubMed ID: 10100593
[TBL] [Abstract][Full Text] [Related]
23. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
[TBL] [Abstract][Full Text] [Related]
25. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
26. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
28. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
29. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.
Takigawa N; Segawa Y; Ueoka H; Kiura K; Tabata M; Shibayama T; Takata I; Miyamoto H; Eguchi K; Harada M
Cancer Chemother Pharmacol; 2000; 46(4):272-8. PubMed ID: 11052624
[TBL] [Abstract][Full Text] [Related]
30. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
31. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
Fokkema E; Groen HJ; Bauer J; Uges DR; Weil C; Smith IE
J Clin Oncol; 1999 Dec; 17(12):3822-7. PubMed ID: 10577855
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule.
Masuda N; Negoro S; Takeda K; Takifuji N; Hirashima T; Yana T; Kurata N; Kuwabara T; Kobayashi S; Kudoh S; Matsui K; Takada M; Fukuoka M
Invest New Drugs; 1998-1999; 16(3):245-54. PubMed ID: 10360604
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
Sessa C; Capri G; Gianni L; Peccatori F; Grasselli G; Bauer J; Zucchetti M; Viganò L; Gatti A; Minoia C; Liati P; Van den Bosch S; Bernareggi A; Camboni G; Marsoni S
Ann Oncol; 2000 Aug; 11(8):977-83. PubMed ID: 11038034
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
Latif T; Wood L; Connell C; Smith DC; Vaughn D; Lebwohl D; Peereboom D
Invest New Drugs; 2005 Jan; 23(1):79-84. PubMed ID: 15528984
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
38. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]